文献速递治疗药物监测与药物基因组学

CPIC专家小组对NAT2等位基因的临床功能分配

Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel.
PubMed 文献 · Clin Pharmacol Ther · 2026-07-31

CPIC的NAT2药物基因 curation 专家小组(PCEP)基于广泛体外和临床文献证据,采用CPIC标准术语对PharmVar收录的59个NAT2星号等位基因进行临床功能分配,其中2个为功能增加、40个为功能降低、10个为功能不确定、7个为功能未知,旨在标准化NAT2药物遗传学检测结果的临床解读。

要点

  • NAT2*1和NAT2*4被分配为功能增加(历史上称为快代谢型)。
  • 40个等位基因被分配为功能降低(历史上称为慢代谢型)。
  • 另有10个功能不确定和7个功能未知的等位基因。

核心结论

  • CPIC NAT2-PCEP采用标准术语完成了59个NAT2星号等位基因的临床功能分配,强调标准化等位基因功能术语和双倍型-表型分配对临床实施NAT2药物遗传学检测的重要性。

研究设计与样本

  • CPIC convened the NAT2-PCEP,由多学科国际成员组成,包括药物基因组学和NAT2分子生物学专家,基于PubMed及其他来源的广泛体外和临床文献进行证据审查。

主要发现

  • NAT2-PCEP对PharmVar收录的59个星号等位基因分配临床功能:2个为功能增加(NAT2*1和NAT2*4),40个为功能降低,10个为功能不确定,7个为功能未知。

关键数值与推荐

  • 功能增加:NAT2*1和NAT2*4(历史上称为快代谢型)。
  • 功能降低:40个等位基因(历史上称为慢代谢型)。
  • 功能不确定:10个等位基因;功能未知:7个等位基因。

临床怎么用

  • 临床解读NAT2药物遗传学检测结果时,应使用CPIC标准术语(功能增加、功能降低、功能不确定、功能未知)对等位基因进行功能分配,并据此进行双倍型-表型预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NAT2 encodes arylamine N-acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 Pharmacogene Curation Expert Panel (PCEP) to assign clinical function to NAT2 star (*) alleles using CPIC's standard terminology. Given the observed impact of NAT2 genetic variability on drug response, CPIC convened the NAT2-PCEP to standardize clinical allele function assignments. The NAT2-PCEP is comprised of multidisciplinary and international members, including researchers, clinicians, and implementers with expertise in pharmacogenomics and NAT2 molecular biology. Extensive in vitro and clinical literature was curated from PubMed and other sources to assess NAT2 genotype-to-phenotype concordance as well as the biochemical function of NAT2 star alleles. The NAT2-PCEP assigned allele clinical function using CPIC's standard terminology (increased, decreased, uncertain, and unknown function) to 59 star alleles cataloged by the Pharmacogene Variation Consortium (PharmVar). Two alleles, NAT2*1 and NAT2*4, were assigned increased function (historically known as rapid), 40 alleles were assigned decreased function (historically known as slow), 10 alleles were assigned uncertain function, and seven alleles were assigned unknown function. Rigorous evidence review and in-depth PCEP discussion were crucial in determining these function assignments. The findings reported here underscore the importance of standardized allele functional terms and diplotype-to-phenotype assignments to further the clinical implementation of NAT2 pharmacogenetic test results.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tibben BM, Hein DW, Whirl-Carrillo M, et al. Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel. Clin Pharmacol Ther. 2026. PMID: 42538601. doi:10.1002/cpt.70420

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。